Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00152464
Status:
COMPLETED
Last Update Posted:
2019-01-22
First Post:
2005-09-08
Brief Title:
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants 12 - 24 Months Suffering From Eczema Atopic Dermatitis and Sensitized to Grass Pollen andor House Dust Mite HDM
Sponsor:
UCB Pharma SA
Organization:
UCB Pharma
Study Overview
Official Title:
The Early Prevention of Asthma in Atopic Children EPAAC Study A Multi-country Double Blind Placebo PLC Controlled Randomized Parallel Group Trial Evaluation of the Efficacy and Safety of Levocetirizine LCTZ 5 mgml Oral Drops -0125 mgkg bw bid Administered for 18 Months in Preventing the Onset of Asthma in 12 to 24 Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and or House Dust Mite Allergens
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Early Prevention of Asthma in Atopic Children EPAAC 24 months study to evaluate the efficacy and safety of levocetirizine LCTZ in preventing the onset of asthma in 12 to 24 months old children
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None